Looking to the future of AD treatment, Dr. Song discusses the unmet need of predicting treatment responses in patients with atopic dermatitis, with the aim of avoiding the trial-and-error process of trying multiple medications.

Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis. Reference: Butler D, et al....
PLAY